HIV

HIV

WHO / Yoshi Shimizu

Despite substantial progress in HIV prevention and treatment, HIV continues to pose a major public health challenge for children. In 2025, an estimated 1.3 million children under 15 years of age were living with HIV globally, with approximately 93,000 new infections and 61,000 AIDS-related deaths. Only 55% of children living with HIV were receiving antiretroviral therapy, highlighting persistent gaps in access to effective treatment. Children with advanced HIV disease remain particularly vulnerable to life-threatening opportunistic infections, underscoring the need for improved prevention, diagnosis and treatment options. At the same time, advances in HIV cure research offer new opportunities, making it essential to ensure that the specific needs of children are considered early in the development of future therapeutic strategies.

Against this backdrop, the 2026 Paediatric Antiretroviral Drug Optimization (PADO-HIV) process, convened by WHO in September–October 2026, brought together experts and stakeholders to review emerging evidence and the evolving HIV drug pipeline, identify priority medicines and formulations, and guide future paediatric drug development. Discussions focused on optimizing and sequencing antiretroviral regimens, prioritizing new oral and long-acting antiretrovirals, and exploring the potential role of novel technologies, including monoclonal antibodies. A dedicated consultation on advanced HIV disease addressed priorities for medicines to prevent and treat opportunistic infections, including opportunities for fixed-dose combinations and co-packaging. The process also considered paediatric-specific research priorities within the emerging HIV cure agenda. Through updated priority, access and watch lists, PADO-HIV aims to provide early signals to developers and research partners, accelerate the availability of optimized treatment options, and promote equitable access to innovation for children living with HIV.

Portfolio products

8 products · PADO-HIV
● Access list: 0    ● Priority list: 4    ● Watch list: 4
0 Access
4 Priority
4 Watch

PADO-HIV priority list 4
ALD 60/30/5 mg
DRV/r 120/20 mg
TAF-XTC ± DTG
Long-acting CAB
PADO-HIV watch list 4
Islatravir
LEN (oral/SC)
Broadly neutralizing antibodies
MAP
Portfolio Update
  • The updated PADO list is anticipated to be shared in Q1 2027.

Contact

Ajay Rangaraj
Email: rangaraja@who.int